CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations

ROS1型 克里唑蒂尼 肺癌 跨膜蛋白 医学 川东北74 癌症研究 腺癌 癌症 内科学 肿瘤科 免疫学 受体 主要组织相容性复合体 恶性胸腔积液 MHC II级 抗原
作者
Weihua Li,Kailun Fei,Lei Guo,Yulan Wang,Chang Shu,Jie Wang,Jianming Ying
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:19 (4): 613-625 被引量:19
标识
DOI:10.1016/j.jtho.2023.12.009
摘要

INTRODUCTION: Variable partners and breakpoints have been reported in patients with ROS1-rearranged NSCLC. Here, we investigated the association of fusion partners and breakpoints with crizotinib efficacy in NSCLCs with common ROS1 fusions. METHODS: DNA and RNA next-generation sequencing (NGS) and immunohistochemistry were performed to characterize ROS1 fusions. RESULTS: Using DNA NGS, we identified ROS1 fusions in 210 cases, comprising 171 common (CD74/EZR/TPM3/SDC4/SLC34A2-ROS1) and 39 uncommon (variants identified in <5%) ROS1 fusion cases. DNA NGS detected variable ROS1 genomic breakpoints in common ROS1 fusions, whereas RNA NGS found ROS1 breakpoints mainly occurring in exons 32, 34 and 35, resulting in long (exon 32) and short (exon 34 or 35) ROS1 fusions. ROS1 immunohistochemistry revealed that membranous and cytoplasmic staining was predominant in long ROS1 fusions, whereas cytoplasmic staining was predominant in short ROS1 fusions (p = 0.006). For patients who received first-line crizotinib, median progression-free survival (mPFS) was lower in patients with long ROS1 fusions than those with short ROS1 fusions (8.0 versus 24.0 mo, p = 0.006). Moreover, mPFS for patients with and without TP53 mutations was 8.0 and 19.0 months, respectively (p = 0.159); mPFS for patients with and without BIM deletion polymorphism was 5.0 and 22.0 months, respectively (p = 0.003). When analyzing together with fusion partners, patients with long CD74/SLC34A2-ROS1 fusions were found to have shorter PFS than those with other ROS1, regardless of the presence or absence of TP53 mutations (p < 0.001 and p = 0.002, respectively). CONCLUSIONS: Long CD74/SLC34A2-ROS1 fusions, which retain transmembrane regions in ROS1 and fusion partners, are associated with poor response to crizotinib independent of TP53 mutations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
许娜发布了新的文献求助10
刚刚
赘婿的应助被milai采纳,获得10
刚刚
纯情的阁的应助被mmmm采纳,获得310
刚刚
1秒前
研友_VZG7GZ的应助被吴陈采纳,获得10
2秒前
yfx发布了新的文献求助30
3秒前
JamesPei的应助被暮离采纳,获得10
3秒前
4秒前
4秒前
4秒前
5秒前
5秒前
温骐华发布了新的文献求助10
5秒前
包容大象完成签到,获得积分10
7秒前
7秒前
8秒前
hushan53完成签到,获得积分10
9秒前
MKW发布了新的文献求助10
10秒前
吹风机发布了新的文献求助10
10秒前
1825810246完成签到 ,获得积分10
10秒前
坠马发布了新的文献求助10
11秒前
12秒前
12秒前
13秒前
13秒前
搜集达人的应助被陆羽采纳,获得10
13秒前
13秒前
wwww完成签到 ,获得积分10
13秒前
Nole的应助被司徒南瓜饼采纳,获得10
14秒前
Mia123的应助被甜美乘云采纳,获得10
14秒前
完美世界的应助被jx采纳,获得10
14秒前
研友_VZG7GZ的应助被看海听风采纳,获得10
14秒前
结实的翠芙完成签到,获得积分10
14秒前
Orange的应助被坠马采纳,获得10
15秒前
爱喝哇哈哈哈完成签到,获得积分10
15秒前
15秒前
16秒前
17秒前
35号发光体完成签到,获得积分10
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163664
求助须知:如何正确求助?哪些是违规求助? 9557817
关于积分的说明 21741980
捐赠科研通 7754358
什么是DOI,文献DOI怎么找? 3428338
关于科研通互助平台的介绍 2553000
邀请新用户注册赠送积分活动 2472943